Clinical trials: MCI Conversion to Dementia
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Mild Cognitive Impairment
A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting
This study will be conducted to evaluate the rate of Alzheimer's disease conversion differences between high-risk mild cognitive impairment (MCI) and low-risk MCI.
- Trial name
- CONCORDE (NCT03448445)
- Testing
- Usual care setting
- Where
- 16 sites in South Korea
- Volunteers
- 201 people
- Sponsor
- Eisai Korea Inc.
Alzheimer s Disease, MCI Conversion to Dementia
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
- Conditions
- Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
- Trial name
- NCT07701161
- Where
- 5 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Neurogen Biomarking LLC